Sjors M. Kas

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

Journal: Cancer research
Published: September 12, 2024

Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation.

Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation.

Journal: Scientific reports
Published: May 26, 2023

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Journal: Nature
Published: September 01, 2022

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Journal: Nature
Published: January 19, 2021

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

Journal: Oncoimmunology
Published: July 03, 2019

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

Journal: Cancer research
Published: March 10, 2018

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Journal: Nature
Published: February 15, 2018

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Journal: Nature genetics
Published: December 09, 2016

Identifying transposon insertions and their effects from RNA-sequencing data.

Identifying transposon insertions and their effects from RNA-sequencing data.

Journal: Nucleic acids research
Published: June 13, 2016

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

Journal: Genes & development
Published: February 10, 2016
Showing 1-10 of 10

Last Updated: 09/26/2026